More than 700 million doses of COVAXIN to be made in a year, Bharat Biotech announced

Bharat Biotech has today announced to increase the capacity to produce 70 million doses of COVAXIN in a year. This goal will be achieved in a phased manner in Hyderabad, and Bengaluru. The company says that capacity expansion in vaccine manufacturing is a long and tedious process. It requires several crores of rupees and many years of investment.

The company said, "Bharat Biotech can expand its capacity to manufacture COVAXIN in a short time." The main reason for this is the availability of specially designed BSL-3 facilities. ”The company said that specialist partners are being sought for vaccine manufacturing in other countries.

Bharat Biotech has partnered with Indian immunologists (IIL) to increase capacity. The process of technology transfer is well underway and IIL has the capability and expertise to manufacture inactivated viral vaccines on a commercial scale and under biosafety control. Bharat Biotech uses a proprietary subsidiary Algel-IMDG, which has now proven to be a safe and effective adjuvant, particularly to stimulate memory T cell responses.

COVAXIN has been approved for emergency use in many countries of the world. With this, negotiations are going on in more than 60 countries. Emergency use has been approved in several other countries including Mexico, the Philippines, Iran, Paraguay, Guatemala, Nicaragua, Guyana, Venezuela, Botswana, Zimbabwe. Talk continues in the United States and many European countries.